Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Dermatol Online J ; 26(10)2020 Oct 15.
Article in English | MEDLINE | ID: mdl-33147661

ABSTRACT

Evolution of technology in the past several decades has undeniably transformed the practice of medicine. Dermatology, a field relying on visual cues, has been particularly impacted by advancement in imaging technologies. The purpose of this study was to review the current status as well as digital future of dermatology. The PubMed database was searched for articles pertaining to digital dermatology using search terms digital dermatology, teledermatology, and dermatopathology education. Digital dermatology has found a role in almost every aspect of dermatology: research, dermatology education and training, and clinical practice including disease prevention, diagnosis, treatment, and patient follow-up. Smartphone applications such VisualDx, MyDermPath, YouDermoscopy serve as diagnostic aid tools and can also help increase the user's knowledge of dermatology. Tools such as multispectral digital skin lesion analysis (MSDSLA) improve diagnostic accuracy and lead to fewer unnecessary biopsies. Teledermatology increases patient satisfaction, as they are able to experience shorter waits times and decreased costs. Underserved communities and those in rural settings are more likely to have a dermatologic evaluation by a specialist via teledermatology. Addressing important topics such as legal framework and updating reimbursement policies will allow for a smoother incorporation of digital dermatology into clinical practice and likely benefit patient care.


Subject(s)
Dermatology , Education, Distance , Skin Diseases , Telemedicine , Dermatology/education , Humans , Mobile Applications , Skin Diseases/diagnosis , Skin Diseases/therapy
2.
Dermatol Online J ; 26(3)2020 Mar 15.
Article in English | MEDLINE | ID: mdl-32609439

ABSTRACT

BACKGROUND: New treatment options for warts include intralesional wart injection with agents such as vitamin D, measles, mumps, and rubella (MMR) vaccine antigen, Bacillus Calmette-Guerin (BCG) antigen, and candida antigen but there have been limited studies to compare their efficacies. OBJECTIVE: The purpose of this systematic review is to compare the efficacy and safety of injectable agents used for the treatment of warts. METHODS: A PubMed search included terms "intralesional wart therapy," "wart injection" and "verruca injection." Articles reviewed were published over 10 years. RESULTS: A total of 43 articles were reviewed; 30 covered studies with more than 10 participants and 13 were case reports, case series, and reviews. In comparison studies intralesional agents have equal or superior efficacy (66%-94.9%) compared to first-line salicylic acid or cryotherapy (65.5-76.5%). One advantage of intralesional injections is the rate of complete resolution of distant warts. LIMITATIONS: Each study varied in their agents, treatment interval, and treatment dose, making comparisons difficult. CONCLUSIONS: Intralesional wart injections are safe, affordable, and efficacious treatments for warts. Physicians should consider intralesional injections for patients with refractory warts, multiple warts, or warts in sensitive areas.


Subject(s)
Injections, Intralesional , Warts/drug therapy , Aminolevulinic Acid/administration & dosage , Anti-Bacterial Agents/administration & dosage , Antiviral Agents/administration & dosage , BCG Vaccine/administration & dosage , Bacterial Vaccines/administration & dosage , Humans , Interferon-alpha/administration & dosage , Mycobacterium , Tuberculin/administration & dosage , Vitamin D/administration & dosage
3.
Expert Opin Pharmacother ; 20(5): 621-629, 2019 04.
Article in English | MEDLINE | ID: mdl-30601075

ABSTRACT

INTRODUCTION: Atopic dermatitis (AD) is one of the most common childhood skin disorders. Multiple mechanisms contribute to the pathology of AD and treatment approaches are directed at these processes. AREAS COVERED: The purpose of this review is to discuss the chemical treatment options for pediatric atopic dermatitis, including immunomodulators and small molecule inhibitors. A systematic literature search was conducted, and publications were reviewed for applicable treatment guidelines. EXPERT OPINION: Topical therapy is first-line for pediatric atopic dermatitis. Providers should work closely with patients and caregivers to promote the success of topical treatments. In disease refractory to topical treatments, systemic agents may be considered. Clinical trials are ongoing for the use of biologics in the treatment of pediatric AD. When choosing the most appropriate treatment, physicians should consider the drug efficacy, potential adverse effects, patient adherence, and quality of life for both patients and caregivers. Additional studies are required to determine the safest and most effective doses for systemic therapy in childhood AD.


Subject(s)
Dermatitis, Atopic/drug therapy , Dermatologic Agents/administration & dosage , Immunologic Factors/administration & dosage , Administration, Cutaneous , Biological Products/administration & dosage , Child , Humans , Medication Adherence , Quality of Life
4.
Expert Rev Clin Pharmacol ; 11(12): 1209-1218, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30449211

ABSTRACT

INTRODUCTION: Psoriasis is a common chronic skin condition that is prevalent worldwide. Despite the numerous treatment options available, discrepancies exist between international guidelines. Areas covered: This review aims to evaluate the current international guidelines for the systemic treatment of psoriasis and psoriatic arthritis. Expert commentary: Most guidelines are unanimous on medication dosing and laboratory monitoring. However, even the most up-to-date guidelines do not include many of the new biologic medications. Guidelines will require frequent updates to include the newer treatments and will soon need to state a recommendation on the use of biosimilars.


Subject(s)
Arthritis, Psoriatic/drug therapy , Practice Guidelines as Topic , Psoriasis/drug therapy , Antirheumatic Agents/administration & dosage , Antirheumatic Agents/therapeutic use , Arthritis, Psoriatic/physiopathology , Biological Products/administration & dosage , Biological Products/therapeutic use , Biosimilar Pharmaceuticals/administration & dosage , Biosimilar Pharmaceuticals/therapeutic use , Dermatologic Agents/administration & dosage , Dermatologic Agents/therapeutic use , Humans , Psoriasis/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...